论文部分内容阅读
目的分析雷贝拉唑、莫沙必利和铝镁加联合治疗反流性食管炎的临床疗效。方法 64例反流性食管炎患者随机分为治疗组34例(雷贝拉唑、莫沙必利和铝镁加联用)及对照组30例(雷贝拉唑、莫沙必利联用),分析两组患者治疗效果。结果治疗组治疗总有效率97.1%明显高于对照组70.0%,症状积分少于对照组,差异均具有统计学意义(P<0.05),两组不良反应对比差异无统计学意义(P>0.05)。结论雷贝拉唑、莫沙必利和铝镁加联合治疗反流性食管炎临床疗效显著,可明显缓解患者临床症状,提高生活质量,且不良反应少,可作为治疗反流性食管炎的理想药物。
Objective To analyze the clinical efficacy of rabeprazole, mosapride and aluminum-magnesium combined therapy for reflux esophagitis. Methods Sixty-four patients with reflux esophagitis were randomly divided into treatment group (rabeprazole, mosapride and Al-Mg plus) and control group (rabeprazole and mosapride) , Analysis of two groups of patients treatment effect. Results The total effective rate of the treatment group was 97.1%, which was significantly higher than that of the control group (70.0%), symptom score was less than that of the control group, the difference was statistically significant (P <0.05), but there was no significant difference between the two groups ). Conclusion The combination of rabeprazole, mosapride and Al-Mg combined with the treatment of reflux esophagitis has a significant clinical effect, which can significantly alleviate the clinical symptoms and improve the quality of life, with fewer adverse reactions and can be used as an ideal treatment for reflux esophagitis drug.